{"id":"W4310962312","doi":"10.1038/s41416-022-02022-y","title":"Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10","year":2022,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"EMD Serono; Genentech; Foundation Medicine; Sierra Oncology; PharmaMar; Newcastle University; MacroGenics; Relay Therapeutics; NGM Biopharmaceuticals; Loxo Oncology; Ribon Therapeutics; Mersana Therapeutics; Eisai; Adaptive Biotechnologies; Pharmacyclics; Agios Pharmaceuticals; Syndax Pharmaceuticals; BeiGene; Mirati Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; TG Therapeutics; Moderna; NuCana; Pfizer; HCA Healthcare; Incyte; Taiho Pharmaceutical; Merck KGaA; Array BioPharma; Revolution Medicines; Exelixis; GlaxoSmithKline; Verastem Oncology; Jounce Therapeutics; Celgene; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Ovarian cancer; BRCA mutation; Adverse effect; Oncology; Cancer; Progressive disease; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001770366,0.0006348372,0.002200542,0.0002992392,0.000304234,0.0008836489,0.0005468996,0.0008705308,0.002418388],"category_scores_gemma":[0.001707137,0.0003406443,0.002251898,0.0004446478,0.0005131921,0.0005106464,0.0002362626,0.00210213,0.0006615108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000721612,"about_ca_system_score_gemma":0.0007201555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001395504,"about_ca_topic_score_gemma":0.002684945,"domain_scores_codex":[0.999257,0.0004007799,0.00004550303,0.00009937819,0.00008781819,0.0001095309],"domain_scores_gemma":[0.9989428,0.0003866349,0.0002234268,0.0001593138,0.00008796372,0.0001998797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7797247,0.009802197,0.04224553,0.001102348,0.008748593,0.0003357741,0.0003070222,0.002076626,0.01812488,0.0001638794,0.003059126,0.1343093],"study_design_scores_gemma":[0.2920294,0.4577973,0.2193565,0.0001950834,0.009895752,0.001100952,0.0002059566,0.001560518,0.006886846,0.0003061968,0.01055509,0.0001103076],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896767,0.005558704,0.0002337328,0.0002597545,0.00006125522,0.000289595,0.001805397,0.00004015691,0.002074761],"genre_scores_gemma":[0.9929577,0.001821227,0.000330566,0.0003227791,0.00008461427,0.0001868788,0.002933102,0.0000247894,0.001338253],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002418388,"threshold_uncertainty_score":0.009362698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01894095934575053,"score_gpt":0.2929071395730326,"score_spread":0.2739661802272821,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}